IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Demonstrates Potential in Alzheimer’s Treatment Market

In response to compelling recent data, India Globalization Capital, Inc. (NYSE MKT: IGC) announced it has made a highly significant novel breakthrough in treating Alzheimer’s disease with tetrahydrocannabinol (THC)—an advancement that could potentially bring much-needed relief to Alzheimer’s sufferers. A recent IGC press release (http://nnw.fm/VlXb3) gave an update on in vitro data that has been compiled from genetically engineered cell lines in an Alzheimer’s disease model, demonstrating that, at varying THC concentrations, the aggregation of Aß protein (the buildup of which has been linked to causing Alzheimer’s) decreases by up to 40 percent. An article further discussing this reads: “IGC stands to benefit in two ways: first, by taking IGC-ADI down the regular FDA route as both a prophylactic and a therapeutic; and second, as a food supplement to be sold in medical dispensaries. The FDA approach to a product labeled as a ‘drug’ is different to one classified as a ‘supplement.’ A drug is considered unsafe until proven otherwise by clinical trials, while a supplement, defined by the Dietary Supplement Health and Education Act (DSHEA) as food, is considered to be prima facie safe. This binal approach allows IGC to secure market share in the medical dispensary segment while IGC-AD1, named Hyalolex, works its way through the FDA approval process.”

To view the full article, visit http://nnw.fm/SeP3n

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us.